effect
tunicamycin
monensin
biosynthesi
intracellular
transport
matur
bovin
herpesviru
typel
glycoprotein
examin
tunicamycin
complet
inhibit
product
infecti
viru
particl
significantli
reduc
incorpor
viral
glycoprotein
presenc
monensin
reduc
amount
infecti
viru
particl
produc
mainli
due
inhibit
viru
releas
rather
viru
product
monensin
slightli
inhibit
viral
glycoprotein
synthesi
effect
compound
infect
indic
glycosyl
requir
product
infecti
viru
though
complet
process
glycoprotein
essenti
addit
egress
virion
infect
cell
probabl
requir
function
golgi
complex
presenc
tunicamycin
monensin
variou
degre
glycosyl
major
glycoprotein
occur
consequ
rate
migrat
differ
normal
glycoprotein
tunicamycin
complet
block
glycosyl
gvp
gvp
contrast
gvp
gvp
llb
partial
glycosyl
presenc
tunicamycin
result
indic
gvp
gvp
nlink
glycoprotein
gvp
gvp
llb
contain
nand
olink
oligosaccharid
side
chain
tunicamycin
block
transport
viral
glycoprotein
cell
surfac
suggest
glycosyl
requir
process
presenc
monensin
viral
glycoprotein
transport
express
cell
surfac
indic
transport
requir
complet
process
glycoprotein
may
occur
via
golgiindepend
pathway
addit
monensintr
infect
cell
could
act
target
cell
antibodydepend
cell
cytotox
assay
thu
complet
glycosyl
may
essenti
mainten
antigen
particip
immun
destruct
cours
infect
herpesvirus
specifi
sever
glycoprotein
spear
spear
locat
viral
envelop
surfac
virusinfect
cell
roizman
spear
glorioso
smith
play
import
role
viral
infect
number
way
recogn
receptor
site
attach
penetr
viru
cell
manservigi
et
u
sarmiento
et
also
antigen
determin
author
reprint
request
address
host
immun
respons
viru
capac
induc
product
neutral
antibodi
mediat
interact
host
immun
system
virion
virusinfect
cell
vestergaard
norrild
norrild
et
al
norrild
et
al
distinct
featur
glycoprotein
carbohydratepeptid
linkag
classifi
two
main
type
nglycosid
oglycosid
linkag
sharon
li
synthesi
process
nlink
oligosaccharid
coa
well
posttransl
event
first
mannoserich
precursor
oligosaccharid
transfer
en
bloc
dolichol
donor
asparagin
residu
nascent
grow
polypeptid
waechter
lennarz
hubbard
ivatt
later
glycosyl
process
oligosaccharid
modifi
sequenti
remov
addit
carbohydr
berger
et
al
contrast
nlink
glycosyl
synthesi
olink
oligosaccharid
occur
sequenti
addit
carbohydr
polypeptid
initi
transfer
nacetylgalactosamin
serin
threonin
residu
berger
et
az
latter
step
involv
process
nlink
oligosaccharid
greater
part
olink
glycosyl
thought
occur
golgi
apparatu
berger
et
al
nlink
oligosaccharid
observ
viral
glycoprotein
previous
investig
ghosh
recent
evid
also
accumul
presenc
olink
oligosaccharid
holm
et
al
oloffson
et
cl
rottier
et
al
shida
dale
johnson
spear
bovin
herpesviru
typel
specifi
structur
polypeptid
supposedli
glycosyl
misra
et
al
although
consider
inform
avail
immun
destruct
infect
cell
babiuk
et
al
rous
et
al
grewal
et
grewal
et
rous
babiuk
thu
far
littl
known
glycoprotein
mediat
immun
lysi
order
character
major
glycoprotein
respect
biochem
immunolog
properti
recent
produc
panel
monoclon
antibodi
van
drunen
littelvan
den
hurk
et
az
avail
monoclon
antibodi
allow
us
identifi
four
uniqu
glycoprotein
respect
precursor
gvp
complex
three
glycopeptid
appar
molecular
weight
two
precursor
approxim
found
gvp
one
precursor
look
gvp
two
precursor
also
occur
dimer
gvp
gvp
llb
one
precursor
van
drunen
littelvan
den
hurk
et
al
van
drunen
littelvan
den
hurk
babiuk
manuscript
prepar
four
uniqu
glycoprotein
express
surfac
virusinfect
cell
except
gvp
particip
antibodi
complementmedi
abc
cytolysi
misra
et
al
van
drunen
littelvan
den
hurk
et
al
order
character
four
major
glycoprotein
use
two
compound
interfer
differ
stage
glycosyl
tunicamycin
act
analog
udpnacetylglucosamin
interfer
format
nacetylglucosamin
pyrophosphoryldolichol
intermedi
therebi
complet
inhibit
synthesi
nlink
oligosaccharid
side
chain
schwartz
datema
consequ
glycoproteincontain
envelop
virus
affect
tunicamycin
way
prevent
matur
product
infecti
viru
schwartz
et
ai
morrison
et
al
nakamura
compan
stohrer
huner
pizer
et
al
monensin
carboxyl
ionophor
abl
equilibr
nak
level
select
na
pressman
although
interfer
varieti
cellular
function
tartakoff
vasal
uchida
et
az
basu
et
al
wilcox
et
al
one
primari
site
action
golgi
apparatu
abolish
proton
gradient
crucial
golgi
function
pressman
envelop
virus
affect
monensin
similar
manner
ie
posttransl
glycosyl
chatterje
et
al
johnson
spear
proteolyt
process
johnson
schlesing
chatterje
et
al
well
protein
secret
strou
lodish
payn
kristensson
transport
viral
envelop
protein
plasma
membran
johnson
schlesing
strou
lodish
alonso
compan
johnson
spear
payn
kristensson
may
inhibit
present
studi
use
tunicamycin
monensin
obtain
inform
contribut
carbohydr
portion
biosynthesi
transport
major
glycoprotein
well
matur
infect
virion
glycosyl
extent
appear
requir
proteolyt
process
transport
express
viral
glycoprotein
cell
surfac
howev
glycosyl
process
complet
process
occur
similarli
partial
complet
process
viral
envelop
glycoprotein
seem
essenti
nucleocapsid
envelop
virion
infect
final
use
two
compound
allow
us
conclud
gvp
probabl
gvp
contain
nlink
carbohydr
wherea
gvp
gvp
llb
nand
olink
oligosaccharid
cell
viru
georgia
bovin
kidney
gbk
cell
grown
monolay
eagl
minim
essenti
medium
mem
grand
island
biolog
co
grand
island
n
supplement
fetal
bovin
serum
fb
grand
island
biolog
co
strain
propag
gbk
cell
quantit
plaqu
microtit
plate
antibodi
overlay
describ
previous
rous
babiuk
potassium
tartar
gradient
analysi
monolay
gbk
cell
infect
multipl
infect
moi
adsorpt
hr
viru
remov
cell
overlaid
methioninefre
mem
contain
fb
tunicamycin
monensin
use
six
hour
later
ml
methionin
amersham
oakvil
ontario
ad
cell
hr
postinfect
viru
purifi
infect
cell
cellassoci
viru
supernat
medium
extracellular
viru
releas
intracellular
viru
infect
cell
sonic
set
set
sonifi
cell
disrupt
model
ultrason
plainsview
n
remov
cell
debri
viru
pellet
centrifug
rpm
hr
rotor
beckman
model
viru
pellet
resuspend
tne
trishydrochlorid
nacl
edta
ph
mild
sonic
layer
onto
linear
potassium
tartrat
gradient
tne
centrifug
rpm
hr
rotor
fraction
collect
assay
radioact
infect
viruscontain
fraction
pool
dilut
tne
centrifug
rpm
hr
rotor
collect
viru
min
ice
sonic
see
set
sonifi
cell
disrupt
model
ultrason
cell
debri
remov
centrifug
rpm
min
rotor
beckman
airfug
rpm
hr
rotor
iec
model
supernat
immedi
use
immunoprecipit
procedur
immunoprecipit
describ
previous
van
drunen
littlevan
den
hurk
et
cd
slightli
modifi
briefli
freshli
prepar
radiolabel
cell
lysat
ripa
buffer
incub
overnight
ice
mous
ascit
fluid
rabbit
igg
antimous
ig
cappel
laboratori
cochranvil
pa
bound
protein
asepharos
bead
pharmacia
montreal
quebec
unbound
antibodi
remov
wash
bead
three
time
ripa
buffer
bead
coat
rabbit
igg
antimous
ig
incub
hr
ice
reaction
mixtur
sepharos
bead
pellet
wash
four
time
ripa
buffer
contain
sd
resuspend
electrophoresi
sampl
buffer
order
dissoci
antigenantibodi
complex
sampl
boil
min
electrophoresi
analysi
polypeptid
polyacrylamid
gel
electwphoresi
high
resolut
sdspage
perform
discontinu
method
laemmli
polypeptid
radiolabel
cell
lysat
immunoprecipit
separ
sdspolyacrylamid
slab
gel
stack
gel
unless
otherwis
mention
electrophoresi
perform
reduc
condit
sampl
contain
analyz
autoradiographi
gel
xray
film
picker
saskatoon
sask
gel
contain
sampl
treat
new
england
nuclear
corp
lachin
quebec
fluorographi
preflash
film
prior
dri
gel
stain
coomassi
blue
visual
molecular
weight
marker
biorad
laboratori
mississauga
ontario
electrophores
parallel
sampl
cell
surfac
immunouoresc
infect
gbk
cell
remov
monolay
mild
trypsin
x
cell
resuspend
bovin
antiserum
reaction
min
cell
wash
three
time
cold
hank
balanc
salt
solut
hbss
react
second
time
dilut
fluoresceinlabel
rabbit
antibovin
igg
antiserum
cappel
laboratori
reaction
min
cell
wash
three
time
cold
hbss
final
resuspend
glycerolpb
mount
glass
slide
observ
aid
fluoresc
microscop
antibodydepend
cell
cytotox
adcc
assay
adcc
assay
perform
microtit
plate
describ
previous
rous
et
al
effector
polymorphonuclear
cell
pmn
target
infect
gbk
cell
cell
ratio
l
control
consist
infect
gbk
target
cell
plu
serum
target
cell
pmn
absenc
antibodi
treatment
infect
target
cell
tunicamycin
monensin
initi
immedi
adsorpt
viru
determin
effect
inhibit
glycosyl
infecti
viru
product
infect
gbk
cell
treat
increas
concentr
tunicamycin
monensin
immedi
infect
tabl
illustr
tunicamycin
monensin
decreas
yield
infecti
differ
concentr
rang
differ
extent
concentr
low
pgml
tunicamycin
suffici
caus
decreas
product
infecti
tunicamycin
concentr
increas
quantiti
infecti
viru
decreas
even
dramat
pgml
infecti
viru
product
neglig
tabl
monensin
also
decreas
total
infecti
viru
product
much
lower
extent
data
shown
sinc
monensin
compound
affect
transport
secret
mechan
cell
assess
whether
decreas
infecti
viru
reflect
reduct
viru
releas
actual
viru
product
tabl
demonstr
monensin
concentr
pm
reduc
extracellular
viru
yield
control
valu
wherea
amount
cellassoci
viru
still
control
valu
trend
continu
increas
concentr
monensin
greater
effect
viru
releas
rather
actual
product
viru
within
cell
assembl
releas
tabl
clearli
demonstr
tunicamycin
well
monensin
inhibit
product
infecti
dosedepend
fashion
addit
appear
infecti
viru
whether
cellassoci
extracellular
produc
presenc
high
enough
concentr
tunicamycin
wherea
infecti
viru
produc
even
high
concentr
monensin
order
obtain
inform
regard
assembl
releas
virion
label
l
methionin
analyz
potassium
tartrat
gradient
gradient
extracellular
cellassoci
viru
untreat
gbk
cell
show
two
peak
radioact
denser
peak
repres
complet
particl
correspond
peak
infect
wherea
lighter
peak
consist
princip
incomplet
particl
lack
dna
misra
et
al
fig
viru
assembl
dramat
affect
presenc
tunicamycin
cell
infect
fig
lb
c
figml
tunicamycin
extracellular
viru
detect
amount
cellassoci
viru
reduc
approxim
control
valu
addit
shift
posit
peak
cellassoci
viru
observ
could
possibl
reflect
alter
size
densiti
conform
virion
infect
detect
peak
fig
monensin
howev
much
less
dramat
effect
viru
assembl
fig
ld
e
piu
well
pm
monensin
quantiti
cellassoci
viru
reduc
control
valu
although
slightli
reduc
peak
cellassoci
viru
show
shift
posit
gradient
similar
observ
tunicamycin
treatment
shift
pronounc
accordingli
reason
amount
infect
detect
peak
fig
agreement
observ
product
hr
postinfect
viru
collect
infect
cell
cellassoci
viru
supernat
medium
extracellular
viru
analyz
potassium
tartrat
gradient
gradient
fraction
bottom
tube
infect
individu
extracellular
x
cellassoci
viru
fraction
c
e
indic
top
fraction
xxx
looo
pfuml
xx
pfumi
x
pfu
ml
x
pfuml
infecti
viru
viru
releas
drastic
reduc
presenc
l
well
monensin
compar
control
valu
releas
fig
viru
low
infect
viral
protein
synthesi
glycosylstt
order
determin
effect
glycosyl
inhibitor
viral
polypeptid
synthesi
glycosyl
mockinfect
infect
gbk
cell
treat
increas
concentr
tunicamycin
monensin
immedi
adsorpt
six
hour
later
cell
label
lp
methionin
hr
postinfect
cell
harvest
incorpor
l
methionin
viral
polypeptid
analyz
sdspage
three
lower
concentr
tunicamycin
effect
incorpor
l
methionin
viral
cellular
polypeptid
observ
pg
ml
tunicamycin
viral
cellular
protein
synthesi
reduc
data
shown
incorpor
glucosamin
individu
viral
polypeptid
significantli
reduc
presenc
increas
concentr
tunicamycin
fig
sinc
glycosyl
cellular
polypeptid
inhibit
extent
data
shown
synthesi
cellular
viral
glycoprotein
probabl
involv
similar
dolicholmedi
carbohydr
transfer
contrast
monensin
littl
rra
r
n
effect
protein
synthesi
glycosyl
viral
cellular
glycoprotein
fig
electrophoret
profil
methioninelabel
viral
polypeptid
synthes
presenc
absenc
tunicamycin
monensin
similar
contrast
pattern
rh
glucosaminelabel
viral
glycopeptid
show
major
glycoprotein
gvp
gvp
gvp
gvp
lla
gvp
llb
gvp
absent
cell
treat
tunicamycin
monensin
wherea
new
band
higher
electrophoret
mobil
appear
fig
ident
glyco
protein
appear
presenc
tunicamycin
mcmensin
monoclon
antibodi
previous
prepar
laboratori
use
establish
ident
faster
migrat
band
appear
presenc
tunicamycin
monensin
mockinfect
infect
cell
treat
two
differ
concentr
tunicamycin
monensin
label
l
methionin
cell
lysat
prepar
precipit
monoclon
antibodi
specif
gvp
lell
gvp
gvp
gvp
llb
precipit
analyz
sdspage
sinc
reduc
condit
normal
use
major
gvp
dissoci
gvp
lla
gvp
gvp
precipit
also
analyz
nonreduc
condit
figur
illustr
monoclon
antibodi
precipit
glycopeptid
gvp
pgvp
gvp
lla
gvp
untreat
virusinfect
cell
label
l
methinin
glucosamin
howev
cell
treat
tunicamytin
one
polypeptid
precipit
may
correspond
nonglycosyl
precursor
form
gvp
ppgvp
van
drunen
littelvan
den
hurk
babiuk
manuscript
prepar
polypeptid
neither
glycosyl
cleav
suggest
gvp
contain
nlink
oli
monoclon
antibodi
immedi
viru
adsorpt
cell
treat
lane
c
lane
j
pgml
tunicamycin
lane
e
k
lane
f
l
phf
monensin
left
untreat
lane
b
g
h
precipit
polypeptid
shown
left
margin
molecular
weight
marker
x
indic
right
margin
gosaccharid
glycosyl
requir
cleavag
gvp
gvp
lla
gvp
contrast
three
glycopeptid
appar
molecular
weight
precipit
monensintr
l
methionineand
cell
glycopeptid
appear
correspond
incomplet
process
form
gvp
gvp
lla
gvp
indic
monensin
inhibit
process
glycoprotein
complet
glycosyl
need
cleavag
gvp
gvp
lla
gvp
analysi
gvp
precipit
nonreduc
condit
confirm
faster
migrat
band
observ
tunicamycin
monensin
treat
cell
nonor
partial
glycosyl
counterpart
gvp
fig
monoclon
antibodi
precipit
gvp
pgvp
untreat
virusinfect
cell
fig
polypeptid
precipit
infect
cell
treat
tunicamycin
one
glycopeptid
appar
molecular
weight
precipit
monensintr
cell
glycopeptid
appear
incomplet
glycosyl
form
gvp
figur
demonstr
gvp
pgvp
precipit
monoclon
antibodi
untreat
virusinfect
cell
label
l
methionin
treatment
cell
tunicamycin
two
polypeptid
appar
molecular
weight
precipit
polypeptid
glycosyl
indic
gvp
contain
nand
olink
oligosaccharid
polypeptid
may
correspond
nonglycosyl
precursor
form
gvp
ppgvp
van
drunen
littelvan
den
hurk
babiuk
manuscript
prepar
cell
treat
monensin
two
glyco
fig
page
analysi
immunoprecipit
l
methioninelabel
lane
f
lane
g
l
polypeptid
mockinfect
lane
g
infect
lane
b
f
h
l
cell
electrophoresi
perform
nonreduc
condit
cell
lysat
precipit
monoclon
antibodi
immedi
viru
adsorpt
cell
treat
lane
c
lane
j
pgml
tunicamycin
lane
e
k
lane
f
l
lm
monensin
left
untreat
lane
b
g
h
peptid
appar
molecular
weight
precipit
glycopeptid
probabl
partial
glycosyl
form
gvp
wherea
glycopeptid
may
correspond
pgvp
gvp
llb
well
precursor
pgvp
llb
precipit
untreat
virusinfect
cell
monoclon
antibodi
fig
one
glycopeptid
appar
molecular
weight
precipit
tunicamycintr
cell
suggest
gvp
llb
contain
nlink
well
olink
oligosaccharid
monensintr
cell
one
glycopeptid
appar
molecular
weight
precipit
probabl
incomplet
process
form
gvp
llb
contrast
glycoprotein
whose
molecular
weight
chang
due
incomplet
process
presenc
tunicamycin
monensin
nonglycosyl
polypeptid
affect
respect
molecular
weight
indic
normal
synthes
presenc
two
compound
exampl
structur
polypeptid
precipit
monoclon
antibodi
shown
fig
express
viral
glycoprotein
cell
surfac
effect
tunicamycin
monensin
transport
viral
glycoprotein
cell
surfac
insert
plasma
membran
examin
surfac
iodin
infect
cell
previous
show
four
major
glycoprotein
gvp
gvp
gvp
gvp
llb
express
surfac
virusinfect
cell
misra
et
az
van
drunen
littelvan
den
hurk
et
cell
surfac
immunofluoresc
confirm
observ
demonstr
viral
glycoprotein
express
surfac
untreat
virusinfect
cell
data
shown
treatment
bhvinfect
cell
pm
monensin
fig
page
analysi
immunoprecipit
lc
methioninelabel
lane
f
aiilucosaminelabel
lane
g
l
polypeptid
mockinfect
lane
g
infect
lane
b
f
h
l
cell
cell
lysat
precipit
monoclon
antibodi
immedi
viru
adsorpt
cell
treat
lane
c
lane
j
pgml
tunicamycin
lane
e
k
lane
f
l
fl
monensin
left
untreat
lane
b
g
h
lane
g
l
polypeptid
mockinfect
lane
g
infect
lane
b
f
h
l
cell
cell
lysat
precipit
monoclon
antibodi
immedi
viru
adsorpt
cell
treat
lane
c
lane
j
pgml
tunicamycin
lane
e
k
lane
f
l
monensin
left
untreat
lane
b
g
h
precipit
polypeptid
shown
left
margin
molecular
weight
marker
x
lo
indic
right
margin
affect
surfac
express
contrast
cell
infect
presenc
pgml
tunicamycin
surfac
immunofluoresc
could
detect
suggest
inhibit
express
viral
glycoprotein
cell
surfac
antibodydepend
cell
cytotox
confirm
tunicamycin
prevent
surfac
express
viral
glycoprotein
see
whether
glycoprotein
express
cell
surfac
presenc
monensin
could
recogn
particip
immunemedi
destruct
infect
cell
includ
cell
target
adcc
assay
presenc
increas
concentr
tunicamycin
cell
infect
caus
reduct
specif
releas
correspond
decreas
final
lack
express
glycoprotein
surfac
infect
cell
fig
contrast
reduct
specif
releas
observ
treatment
infect
cell
increas
concentr
monensin
fig
result
support
previou
result
show
tunicamycin
inhibit
cell
surfac
express
antigen
wherea
monensin
discuss
gbk
cell
fail
produc
infecti
viru
particl
treat
tunicamycin
extracellular
small
amount
cellassoci
noninfecti
viru
detect
viru
produc
circumst
consid
defect
sinc
infecti
lower
densiti
potassium
tartrat
gradient
infecti
viru
increas
concentr
tunicamycin
viral
well
cellular
glycoprotein
synthesi
specif
increasingli
inhibit
consist
known
inhibitori
effect
tunicamycin
nlink
glycosyl
eukaryot
cell
schwartz
datema
effect
tunicamycin
glycosyl
protein
suggest
like
envelop
virus
ghosh
use
cellular
enzym
glycosyl
protein
produc
presenc
tunicamycin
essenti
lack
nlink
oligosaccharid
side
chain
may
explain
lower
densiti
noninfecti
viru
particl
produc
tunicamycintr
cell
influenc
tunicamycin
infect
indic
glycosyl
viral
protein
requir
product
infecti
viru
phenomenon
previous
report
sever
envelop
virus
schwartz
et
al
morrison
et
al
nakamura
compan
stohrer
hunter
pizer
et
al
gbk
cell
treat
monensin
reduc
amount
infecti
viru
particl
produc
howev
reduct
viru
product
per
se
nbt
dramat
viru
releas
instanc
viru
releas
complet
inhibit
may
due
fact
high
cocnentr
monensin
slightli
cytopath
therefor
cell
may
easili
disrupt
consequ
releas
cellassoci
viru
presenc
monensin
viral
cellular
glycoprotein
synthesi
slightli
reduc
consist
suppos
inhibitori
effect
monensin
golgi
complex
pressman
greater
part
process
nlink
oligosaccharid
synthesi
olink
oligosaccharid
thought
occur
berger
et
az
suggest
protein
synthes
presenc
monensin
lack
fulli
process
nlink
andor
olink
carbohydr
mani
explain
somewhat
lower
densiti
cellassoci
viru
particl
produc
monensintr
cell
also
indic
complet
process
fig
antibodydepend
cell
cytotox
gbk
cell
infect
moi
variou
concentr
tunicamycin
monensin
ad
cell
immedi
viru
adsorpt
maintain
cell
harvest
hr
postinfect
effector
pmn
target
cell
harvest
hr
postinfect
effector
pmn
target
cell
ratio
assay
done
triplic
nonspecif
releas
case
less
glycoprotein
need
infect
sinc
consider
fraction
virion
associ
monensintr
cell
still
infecti
even
though
glycoprotein
fulli
process
similarli
result
report
influenza
viru
alonso
compan
campadellifium
et
az
johnson
spear
observ
monensin
mainli
affect
releas
virion
support
proposit
golgi
apparatu
involv
egress
herpesvirion
cell
johnson
spear
use
monoclon
antibodi
specif
major
glycoprotein
shown
nonor
partial
glycosyl
polypeptid
lower
molecular
weight
found
tunicamycinand
monensintr
cell
antigen
relat
glycoprotein
gvp
gvp
gvp
gvp
llb
tunicamycintr
cell
nonglycosyl
counterpart
gvp
found
may
precursor
polypeptid
pp
gvp
van
drunen
littelvan
den
hurk
babiuk
manuscript
prepar
indic
gvp
contain
nlink
carbohydr
side
chain
although
major
gvp
normal
cleav
gvp
lla
gvp
nonglycosyl
polypeptid
present
tunicamycintr
cell
cleav
appar
glycosyl
requir
proper
conform
andor
locat
polypeptid
need
cleavag
nonglycosyl
counterpart
gvp
detect
tunicamycintr
cell
may
sever
reason
observ
report
nonglycosyl
polypeptid
sometim
difficult
detect
complet
translat
glycoprotein
mrna
may
depend
cotransl
addit
nlink
oligosaccharid
side
chain
ii
nonglycosyl
polypeptid
may
suscept
degrad
host
cell
proteas
iii
nonglycosyl
polypeptid
may
aggreg
thu
solubil
schwartz
et
al
leavitt
et
al
diggelman
gibson
et
ak
pixer
et
al
stallcup
field
whichev
reason
correct
suggest
gvp
may
nlink
glycoprotein
one
partial
glycosyl
counterpart
gvp
found
tunicamycintr
cell
suggest
gvp
contain
nlink
well
olink
carbohydr
side
chain
intens
partial
glycosyl
polypeptid
indic
consider
fraction
oligosaccharid
gvp
link
addit
small
amount
nonglycosyl
polypeptid
detect
may
precursor
polypeptid
pp
gvp
van
drunen
littelvan
den
hurk
babiuk
manuscript
prepar
similarli
one
partial
glycosyl
counterpart
gvp
llb
present
tunicamycin
treat
cell
indic
gvp
llb
also
contain
nlink
olink
oligosaccharid
side
chain
presenc
monensin
increas
electrophoret
mobil
four
glycoprotein
observ
indic
process
nlink
oligosaccharid
andor
synthesi
olink
oligosaccharid
inhibit
monensin
shown
block
process
sindbi
viru
johnson
schlesing
johnson
spear
wensk
et
az
glycoprotein
highmannos
stage
howev
glycoprotein
observ
monensintr
infect
cell
correspond
normal
precursor
four
glycoprotein
suggest
partial
process
beyond
highmannos
stage
occur
order
determin
whether
differ
due
viru
cell
system
use
well
grown
presenc
monensin
three
differ
cell
line
experi
data
shown
demonstr
effect
monensin
glycoprotein
independ
cell
line
use
addit
wherea
glycoprotein
process
beyond
highmannos
stage
presenc
monensin
glycoprotein
block
highmannos
stage
agreement
previous
mention
observ
johnson
spear
wensk
et
ah
thu
differ
effect
monensin
glycoprotein
appear
reflect
viru
rather
cell
line
tunicamycin
block
transport
bhv
glycoprotein
cell
surfac
consist
previou
report
number
envelop
virus
nakamura
compan
norrild
pederson
payn
kristensson
peak
et
al
clearli
suggest
glycosyl
requir
process
contrast
data
report
johnson
spear
glycoprotein
transport
express
cell
surfac
presenc
monensin
reason
discrep
fulli
understood
could
relat
viru
cell
system
use
discrep
uncommon
sinc
mani
report
effect
monensin
transport
glycoprotein
cell
surfac
controversi
often
shown
monensin
prevent
transport
johnson
schlesing
alonso
compan
johnson
spear
payn
kristensson
sometim
effect
observ
alonso
compan
chatterje
et
al
one
commun
describ
blockag
transport
vsv
influenza
viru
glycoprotein
surfac
babi
hamster
kidney
cell
wherea
influenza
hemagglutinin
vsv
g
protein
express
surfac
madindarbi
canin
kidney
mdck
cell
alonso
compan
result
indic
viru
cell
may
influenc
final
result
observ
presenc
monensin
glycoprotein
express
cell
surfac
wherea
glycoprotein
johnson
spear
may
due
mention
differ
degre
glycosyl
appear
reflect
viru
furthermor
glycoprotein
may
transport
vesicl
like
influenza
hemagglutinin
whose
format
depend
upon
golgi
complex
thu
insensit
monensin
infect
cell
grown
presenc
tunicamycin
could
act
target
cell
adcc
assay
one
would
expect
sinc
glycoprotein
express
surfac
similar
result
report
infect
cell
treat
tunicamycin
norrild
pederson
contrast
monensin
affect
effici
lysi
adcc
assay
even
though
glycoprotein
synthes
presenc
compound
incomplet
glycosyl
thu
antibodi
recogn
glycoprotein
produc
presenc
monensin
kill
virusinfect
cell
adcc
suggest
alter
glycosyl
induc
compound
affect
antigen
glycoprotein
consequ
although
glycosyl
may
requir
proper
fold
conform
glycoprotein
complet
carbohydr
portion
may
need
may
play
major
role
antigen
immunogen
glycoprotein
